Kliiniliste Uuringute Keskus OÜ — Clinical Trial Site

26 Registered trials

6 Currently recruiting

Organisation

Kliiniliste Uuringute Keskus OÜ

Location

Tartu Linn, Estonia

Identifier

ORG-100042285

Address

Sobra Tn 54/1, 50106, Estonia

Departments

Clinical Research Centre
Dermatovenerology
EE001
EE10003
Kliiniliste Uuringute Keskus OÜ
n/a
NA

Clinical trials at this site (26)

Search interface

A phase III, randomised, double-blind, multicentre study comparing the efficacy, safety, and immunogenicity of proposed tocilizumab biosimil… Not authorised

2022-501361-44-00 Adult patients of either gender with active moderate to 5
A study to evaluate the efficacy, immunogenicity, and safety of an RSV and hMPV VLP vaccine compared with placebo in participants aged 60 ye… Pending

2024-513740-28-00 Respiratory Syncytial Virus and Human Metapneumovirus 5
A Phase 3, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib in Subjects with Active Pso… Pending

2025-522586-30-00 Psoriatic Arthritis 5
A study on the immune response and safety of an investigational chickenpox vaccine and a marketed measles, mumps and rubella vaccine when ad… Recruiting

2024-518840-18-00 Varicella 5 2025-12-10
An Extension Study to Evaluate Safety, Efficacy, and Durability of Response to ESK-001 for Moderate to Severe Plaque Psoriasis (ONWARD3) Recruiting

2024-511166-36-00 Moderate to Severe Plaque Psoriasis 5 2025-06-13
Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants from Approximately 2 Months of Age Recruiting

2023-507600-32-00 Pneumococcal Immunization 5 2025-05-22
A Phase 3 program evaluating the effect of filgotinib in subjects with active axial spondyloarthritis Recruiting

2022-501354-10-01 axial spondyloarthritis 5 2023-06-21
A study on the immune response and safety of an investigational chickenpox vaccine when given to healthy children 12 to 15 months of age. Recruiting

2024-515869-33-00 Varicella 5 2025-07-08
A Study of Zasocitinib in Adults with Psoriatic Arthritis Who Have Not Taken Biologic Medicines Recruiting

2024-513111-27-00 Psoriatic Arthritis 5 2025-06-26
A Phase 3 Study to Assess the Safety and Immunogenicity of High-dose Influenza Vaccine in Adults ≥ 60 years of Age Ended

2024-519743-15-00 Influenza immunisation 5 2025-10-20
Study of the Safety and lmmunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, T… Ended

2024-512271-13-00 Pneumococcal immunisation 5 2025-05-08
An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients with Psoriatic Arthritis. Ended

2022-501480-41-00 Psoriatic Arthritis 5 2023-04-06
A study on the long-term efficacy, safety and persistence of immune response of a vaccine against Herpes Zoster in older adults. Ended

2023-505255-51-00 Herpes Zoster 5 2022-08-08
A Study of the Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis Ended

2023-504734-21-00 Psoriatic arthritis (PsA) 5 2021-08-30
Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study for Moderate to Severe Plaque Psoriasis to Evaluate Efficac… Ended

2023-508959-39-00 Moderate to Severe Plaque Psoriasis 5 2025-02-20
A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) wi… Ended

2023-506664-14-00 Rheumatoid Arthritis 5 2024-10-24
A Study to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Influenza Vaccine Compared with a Licensed Influenza … Ended

2024-516240-26-00 Influenza 5 2024-10-11
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to… Ended

2023-504564-42-00 Moderate to Severe Rheumatoid Arthritis 4 2024-04-08
A phase IIb study to Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Plaque Psoriasis Ended

2023-506477-35-00 moderate to severe plaque psoriasis 4 2024-04-02
Efficacy, safety, PK, PD, and immunogenicity of BP16 in post-menopausal osteoporosis Ended

2023-503790-37-00 Post-Menopausal Osteoporosis 5 2024-01-09
A study on the reactogenicity, safety, immune response, and efficacy of a targeted immunotherapy against HSV in healthy participants aged 18… Ended

2024-510571-37-00 Herpes Simplex 7 2023-12-06
The Celljuvant study, A phase 3 Immunogenicity and Safety Study of aQIVc HD Vaccine in Adults aged 50 years and older. Ended

2023-503763-42-00 Healthy individuals or individuals with stable comorbid 5 2023-11-03
To access the effect of SCD-044 in treatment of moderate to severe atopic dermatitis Ended

2024-511615-16-00 atopic dermatitis 4 2023-08-25
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon) Ended

2022-501538-44-00 Atopic Dermatitis 5 2023-04-25